Previous 10 | Next 10 |
Merger activity decreased last week with two new deals announced, and one deal closing. One of the two new deals announced last week was on our list of potential deals and the other one was a "going private" transaction. According to Reuters, Australian antitrust regulators expressed conc...
NEW YORK , June 17, 2020 /PRNewswire/ -- Independent Bank Group Inc. (NASD: IBTX) will replace Progenics Pharmaceuticals Inc. (NASD: PGNX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, June 22 . S&P Small-Cap 600 constituent Lantheus Holdings I...
Independent Bank Group (NASDAQ: IBTX ) is up 6.4% postmarket on word it's joining the S&P SmallCap 600 index . More news on: Independent Bank Group, Inc., Progenics Pharmaceuticals, Inc., Stocks on the move, Financial stocks news, Read more ...
Lantheus Holdings (NASDAQ: LNTH ) shareholders voted overwhelmingly in favor of issuing common stock related to its previously announced merger with Progenics Pharmaceuticals (NASDAQ: PGNX ). 99% of the votes cast backed the plan. More news on: Lantheus Holdings, Inc., Progenics Pharmace...
NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, announced that at a special meeting of its stockholders h...
Gainers: ACB +26.4% . SCVL +5.8% . PGNX +4.4% . EVLO +3.4% . OPRA +3.4% . More news on: Aurora Cannabis Inc., Shoe Carnival, Inc., Progenics Pharmaceuticals, Inc., Stocks on the move, , Read more ...
- Met Primary Endpoint with a Correct Localization Rate of 84.8–87.0% - - 63.9% Change in Disease Management Plan Based on PyL Imaging Results - - Planned NDA Submission On Track for Early Third Quarter 2020 - NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceutica...
Call Start: 8:30 Call End: 8:49 Progenics Pharmaceuticals, Inc. (PGNX) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Melissa Downs - Head, IR Ann MacDougall - Interim Chair of the Board David Mims - Interim CEO & CFO Asha Das - CMO Bryce...
Progenics Pharmaceuticals (NASDAQ: PGNX ): Q1 GAAP EPS of -$0.19 beats by $0.03 . More news on: Progenics Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and Radiopharmaceutical Therapeutics Portfolio Planned NDA Submission for PyL TM On Track for Early Third Quarter 2020 First Quarter Sal...
News, Short Squeeze, Breakout and More Instantly...
Progenics Pharmaceuticals Inc. Company Name:
PGNX Stock Symbol:
NASDAQ Market:
Progenics Pharmaceuticals Inc. Website:
The second half of the year could provide some solid wins for investors in the cancer therapeutics market. In recent years, Wall Street has flocked to many of these biotechnology companies because of their potential to deliver cutting-edge treatments and generate long-term returns. As cancer ...
Biopharma Dynavax Technologies (NASDAQ: DVAX) is one of many companies racing to develop a COVID-19 vaccine. Like many coronavirus-focused companies, Dynavax has seen its shares rise on the ongoing concern related to the pandemic -- in its case, by 50% year to date. While investors may co...
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it...